Scott Serels
Research Subjects
Scott Serels has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Glori Short
Obstetrics/Gynecology Cullman, Cullman City, USA
2 shared publications- Marc R. Toglia
Urogynecology Associates of Philadelphia, Main Line HealthCare - Center for Female Pelvic Floor Disorders, Media, PA, USA
1 shared publication Michael Douso
Tallahassee Pelvic Floor Disorders Clinic, Capital Regional Medical Center, Tallahassee, USA
1 shared publicationMichael Duoso
Tallahassee Pelvic Floor Disorders Clinic, Capital Regional Medical Center, Tallahassee, USA
1 shared publicationSergio Forero-Schwanhaeuser
GlaxoSmithKline, King Of Prussia, PA, USA
1 shared publicationWeizhong He
Astellas Pharma Global Development Inc., Deerfield, IL, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Obstetrics and Gynecology
- Vol. 4 (3) , 68-71
Single incision slings: Past, present, and future
Single incision slings: Past, present, and future
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Obstetrics and Gynecology
- Vol. 4 (3) , 68-71
Open AccessSingle incision slings: Past, present, and future
Single incision slings: Past, present, and future
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2277-2285
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms
It is widely recognized that patient perception of overactive bladder (OAB) symptoms can vary considerably from mild to severe bother. This post hoc analysis reports outcomes in patients with severe OAB symptoms at baseline taken from the VESIcare Efficacy and Safety in PatieNts with Urgency Study (VENUS). VENUS was a 12-week, randomized, double-blind, placebo-controlled trial of solifenacin (5 or 10 mg/day, flexibly dosed) in OAB patients. The primary endpoint in VENUS was mean change from baseline to study end in urgency episodes/day using 3-day bladder diaries. Secondary endpoints included other diary endpoints (frequency, incontinence, and nocturia), warning time (WT; time between first sensation of urgency to voiding), and patient-reported outcome (PRO) measures of urgency (the Indevus Urgency Severity Scale [IUSS] and Urgency Perception Scale [UPS]) and of symptom bother and health-related quality of life (HRQL) (the Patient Perception of Bladder Condition [PPBC] and Overactive Bladder Questionnaire). For this analysis, severe OAB was defined as baseline PPBC score ≥5 (1 = no problems, 6 = many severe problems). Trial registration: NCT00454896 In total, 158/707 (22.3%) patients in the full analysis set (FAS) reported severe OAB symptoms. Solifenacin reduced mean urgency episodes/day versus placebo in the severe subgroup (−4.6 vs. −3.1, p = 0.1150), similar to the significant reduction observed in the FAS (−3.9 vs. −2.7, p < 0.0001). Solifenacin also improved the other diary endpoints and PRO measures in the severe subgroup; these changes were consistent with the significant solifenacin- versus placebo-related improvements for the FAS. Treatment-emergent adverse events were mostly mild/moderate, and few patients taking solifenacin or placebo discontinued treatment in the severe subgroup (4.5% vs. 6.5%) or FAS (6.5% vs. 4.6%). Key limitations are that VENUS was not powered to detect treatment differences in subgroups, and that the lack of a standardized definition of OAB symptom severity may limit the generalizability of the findings. Patients with severe OAB symptoms showed objective and subjective improvements in symptoms, symptom bother, HRQL, and urgency severity with solifenacin similar to the FAS. Solifenacin was also well-tolerated in this subgroup.
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2277-2285
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms
It is widely recognized that patient perception of overactive bladder (OAB) symptoms can vary considerably from mild to severe bother. This post hoc analysis reports outcomes in patients with severe OAB symptoms at baseline taken from the VESIcare Efficacy and Safety in PatieNts with Urgency Study (VENUS). VENUS was a 12-week, randomized, double-blind, placebo-controlled trial of solifenacin (5 or 10 mg/day, flexibly dosed) in OAB patients. The primary endpoint in VENUS was mean change from baseline to study end in urgency episodes/day using 3-day bladder diaries. Secondary endpoints included other diary endpoints (frequency, incontinence, and nocturia), warning time (WT; time between first sensation of urgency to voiding), and patient-reported outcome (PRO) measures of urgency (the Indevus Urgency Severity Scale [IUSS] and Urgency Perception Scale [UPS]) and of symptom bother and health-related quality of life (HRQL) (the Patient Perception of Bladder Condition [PPBC] and Overactive Bladder Questionnaire). For this analysis, severe OAB was defined as baseline PPBC score ≥5 (1 = no problems, 6 = many severe problems). Trial registration: NCT00454896 In total, 158/707 (22.3%) patients in the full analysis set (FAS) reported severe OAB symptoms. Solifenacin reduced mean urgency episodes/day versus placebo in the severe subgroup (−4.6 vs. −3.1, p = 0.1150), similar to the significant reduction observed in the FAS (−3.9 vs. −2.7, p < 0.0001). Solifenacin also improved the other diary endpoints and PRO measures in the severe subgroup; these changes were consistent with the significant solifenacin- versus placebo-related improvements for the FAS. Treatment-emergent adverse events were mostly mild/moderate, and few patients taking solifenacin or placebo discontinued treatment in the severe subgroup (4.5% vs. 6.5%) or FAS (6.5% vs. 4.6%). Key limitations are that VENUS was not powered to detect treatment differences in subgroups, and that the lack of a standardized definition of OAB symptom severity may limit the generalizability of the findings. Patients with severe OAB symptoms showed objective and subjective improvements in symptoms, symptom bother, HRQL, and urgency severity with solifenacin similar to the FAS. Solifenacin was also well-tolerated in this subgroup.
- 5 February 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (5) , 617
Erratum to: Preliminary findings with the Solyx™ single-incision sling system in female stress urinary incontinence
- 5 February 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (5) , 617
Erratum to: Preliminary findings with the Solyx™ single-incision sling system in female stress urinary incontinence
- 19 December 2009
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (5) , 557-561
Preliminary findings with the Solyx™ single-incision sling system in female stress urinary incontinence
Introduction and hypothesis The aim of this study was to test the safety and efficacy of the Solyx single-incision sling (SIS) in women with stress urinary incontinence (SUI). Methods A retrospective study of 63 women who had undergone implantation at three medical centers (December–March 2009) was conducted. Results Mean patient age was 51 years (range, 30–87 years); 37 (59%) patients had concomitant urogynecological procedures. At a mean follow-up of 6.5 months (range, 5–8 months), 95% of patients were dry on the basis of subjective and objective assessment. Two patients experienced transient urinary retention, which resolved spontaneously. No complications of the procedure were reported, including no bladder, bowel, vessel, or nerve perforations and no erosions or extrusions. No pain was reported that was attributed to the implant. Conclusions The very early efficacy results indicate that the Solyx SIS system is an attractive treatment option for SUI. The minimal number of steps involved in the procedure will facilitate uptake of the technique.
- 19 December 2009
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (5) , 557-561
Preliminary findings with the Solyx™ single-incision sling system in female stress urinary incontinence
Introduction and hypothesis The aim of this study was to test the safety and efficacy of the Solyx single-incision sling (SIS) in women with stress urinary incontinence (SUI). Methods A retrospective study of 63 women who had undergone implantation at three medical centers (December–March 2009) was conducted. Results Mean patient age was 51 years (range, 30–87 years); 37 (59%) patients had concomitant urogynecological procedures. At a mean follow-up of 6.5 months (range, 5–8 months), 95% of patients were dry on the basis of subjective and objective assessment. Two patients experienced transient urinary retention, which resolved spontaneously. No complications of the procedure were reported, including no bladder, bowel, vessel, or nerve perforations and no erosions or extrusions. No pain was reported that was attributed to the implant. Conclusions The very early efficacy results indicate that the Solyx SIS system is an attractive treatment option for SUI. The minimal number of steps involved in the procedure will facilitate uptake of the technique.
- 11 September 2007
- Published by Springer Nature in Current Urology Reports
- Vol. 8 (5) , 359-363
Thoughts on midurethral synthetic slings
Since the early 1900s, there have been many attempts to correct stress urinary incontinence (SUI) in women. Over the years, it became accepted that the most effective way to correct SUI involved a procedure that supports the urethra. This simple premise spurred major innovations in the 1970s and 1980s by Shlomo Raz and Tom Stamey, many of which proved difficult to reproduce and were not universally accepted. In the mid-1990s, however, Ulf Ulmsten and Peter Petros revolutionized treatment of SUI, using a synthetic sling at the midurethra in a tension-free fashion. The urologic and urogynecologic world forever changed. In the last decade, further innovations have been based on these principles. There are currently three main types of synthetic sling procedures, including the retropubic synthetic sling, the obturator synthetic sling, and the single-incision synthetic sling.
- 11 September 2007
- Published by Springer Nature in Current Urology Reports
- Vol. 8 (5) , 359-363
Thoughts on midurethral synthetic slings
Since the early 1900s, there have been many attempts to correct stress urinary incontinence (SUI) in women. Over the years, it became accepted that the most effective way to correct SUI involved a procedure that supports the urethra. This simple premise spurred major innovations in the 1970s and 1980s by Shlomo Raz and Tom Stamey, many of which proved difficult to reproduce and were not universally accepted. In the mid-1990s, however, Ulf Ulmsten and Peter Petros revolutionized treatment of SUI, using a synthetic sling at the midurethra in a tension-free fashion. The urologic and urogynecologic world forever changed. In the last decade, further innovations have been based on these principles. There are currently three main types of synthetic sling procedures, including the retropubic synthetic sling, the obturator synthetic sling, and the single-incision synthetic sling.
- 31 March 2004
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (6) , 791-801
The wet patient: understanding patients with overactive bladder and incontinence
Overactive bladder (OAB) is a constellation of lower urinary tract symptoms, including urinary frequency and urgency,which can occur with or without urinary incontinence. Incontinence is present in over half of female patients with OAB. This condition affects more than 33 million Americans and imposes considerable economic, social, and psychological burdens. Although continued improvements in the pharmacologic management of lower urinary tract disorders have led to the availability of well-tolerated, characteristic features, prevalence and epidemiology, effective treatment options, the symptoms of OAB are generally underreported by patients and under treated by healthcare professionals. Heightened awareness of the multifaceted disease burden imposed by OAB and increased understanding of the characteristics of patients who are likely to be most severely affected, in particular those who suffer from incontinence, may improve the timely identification, diagnosis, and clinical management of the syndrome, enhancing both the health and quality of life of these patients. This review will summarize the clinical consequences, and management of OAB, with particular focus on the incontinent patient.
- 31 March 2004
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (6) , 791-801
The wet patient: understanding patients with overactive bladder and incontinence
Overactive bladder (OAB) is a constellation of lower urinary tract symptoms, including urinary frequency and urgency,which can occur with or without urinary incontinence. Incontinence is present in over half of female patients with OAB. This condition affects more than 33 million Americans and imposes considerable economic, social, and psychological burdens. Although continued improvements in the pharmacologic management of lower urinary tract disorders have led to the availability of well-tolerated, characteristic features, prevalence and epidemiology, effective treatment options, the symptoms of OAB are generally underreported by patients and under treated by healthcare professionals. Heightened awareness of the multifaceted disease burden imposed by OAB and increased understanding of the characteristics of patients who are likely to be most severely affected, in particular those who suffer from incontinence, may improve the timely identification, diagnosis, and clinical management of the syndrome, enhancing both the health and quality of life of these patients. This review will summarize the clinical consequences, and management of OAB, with particular focus on the incontinent patient.